Health Trials

Pancreatic Adenocarcinoma Advanced or Metastatic

3

Review clinical trials related to Pancreatic Adenocarcinoma Advanced or Metastatic. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

CT-95 in Advanced Cancers Associated With Mesothelin Expression

This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with advanced (recurrent, unresectable, or metastatic) cancers associated with MSLN expression.

Participants needed: 70
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Context Therapeutics Inc.Updated: Jun 12, 2026Locations: 9
Eligibility criteria

ECOG 0 or 1 [+3]

Uncontrolled significant active infection or any medical or other condition that... [+3]

Read more
Status: Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations

This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-8989 in patients with advanced solid tumors harboring KRAS G12D mutations.

Participants needed: 178
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Shenzhen Ionova Life Sciences Co., Ltd.Updated: Jun 10, 2026Locations: 1
Eligibility criteria

Written informed consent obtained. [+9]

Have protocol-defined toxicities within 28 days before the start of study treatm... [+17]

Read more
Status: Recruiting

Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

PANThEON is a randomized, open-label, multicenter phase III trial aimed at comparing the switch maintenance with gemcitabine plus nab-paclitaxel (ARM B) versus mFOLFIRINOX continuation (ARM A) in terms of overall survival (OS) in patients with unresectable LAD or mPDAC without disease progression following 3 months of induction mFOLFIRINOX triplet chemotherapy.

Participants needed: 340
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Gruppo Oncologico del Nord-OvestUpdated: May 25, 2025Locations: 28
Eligibility criteria

Patient able and willing to provide written informed consent and to comply with... [+18]

Pancreatic neuroendocrine, acinar, squamous/adenosquamous, or islet tumors. [+13]

Read more